In Brief
Small molecules with photochromic properties have potential for precise drug therapeutics. Rovira et al. present OptoGluNAM4.1, allowing reversible mGlu4 activity photocontrol in vitro and in vivo that can be used to dissect the physiological roles of this receptor in the nervous system.
INTRODUCTION
Photopharmacology is based on the use of light-sensitive ligands for the optical control of specific proteins in cells, tissues, or live animals. This innovative and unconventional approach uses light for the precise control of drug activity, which in combination with spatiotemporal patterns of illumination can enable localized therapeutic effects and dosage adjustment to maximize efficacy and minimize side effects (Gorostiza and Isacoff, 2008) . The photochromic ligands can rapidly and reversibly switch on or off the activity of a protein with light in delimited and specific localizations and time intervals, and have the potential for precise drug therapeutics (Reiner et al., 2015) . G-proteincoupled receptors (GPCRs) represent a large family of transmembrane receptors with fertile therapeutic targets for drug development (Conn et al., 2009) . Metabotropic glutamate (mGlu) receptors are class C GPCRs that play important roles in a broad range of CNS functions with promise for the treatment of various psychiatric and neurological disorders (Nicoletti et al., 2011) . In particular, the mGlu 4 subtype has recently attracted much attention due to its involvement in several diseases, including chronic pain (Vilar et al., 2013; Huang et al., 2014) .
Owing to the difficulty in developing subtype selective orthosteric ligands, significant effort has recently been directed toward identifying drugs that act at mGlu receptor allosteric sites (Conn et al., 2009; Wenthur et al., 2014) . Azobenzene-containing photoswitchable molecules have been used for optical control of mGlu receptors at their orthosteric (Levitz et al., 2013) and allosteric (Pittolo et al., 2014) sites.
RESULTS AND DISCUSSION
In the present work, OptoGluNAM4.1 (compound 1, Figure 1A ) emerged from a screening of photoisomerizable azobenzene molecules as an antagonist, decreasing both mGlu 4 basal-mediated and orthosteric agonist-mediated activities in a dosedependent manner ( Figure 1B , left top panel, and Figure S1 ). Saturation of the inhibitory effect indicated either allosteric behavior of the drug or solubility issues. In order to test the allosteric properties of OptoGluNAM4.1, we performed a series of experiments with the full receptor ( Figure 1B , right top panel), the receptor containing a mutation that renders mGlu 4 insensitive to glutamate ( Figure 1B , left bottom panel), and a headless truncated version that lacks the extracellular domain where orthosteric agonists bind ( Figure 1B , right bottom panel). These receptor constructs were activated by the known allosteric agonist VU0155041 (Rovira et al., 2015) and competed with increasing concentrations of OptoGluNAM4.1, which reduced mGlu 4 activation. Overall, these results confirmed the interaction of the molecule in an allosteric site located in the transmembrane domain and having a typical profile of a negative allosteric modulator (NAM), which to our knowledge is the second mGlu 4 NAM described so far (Utley et al., 2011) , in contrast with the high number of positive allosteric modulators (PAMs) discovered for this receptor (Rovira et al., 2015) . OptoGluNAM4.1 showed no PAM activity over any mGlu subtype at high concentrations, and, besides the mGlu 4 NAM activity, only a partial NAM effect on mGlu 7 was observed ( Figure S1 ). A computational study performed with a molecular model of the mGlu 4 receptor ( Figure 1C ) suggests an OptoGluNAM4.1 interaction in the transmembrane domain, similar to that of PAMs of mGlu 4 (Rovira et al., 2015) and NAMs of mGlu 1 and mGlu 5 (Harpsøe et al., 2015) . The mutation of two amino acid positions (L756S and V826M) was aimed at topologically delimiting the boundaries of the putative allosteric binding site in the mGlu 4 protein ( Figure S1 and Movie S1). When OptoGluNAM4.1 was tested on L756S mGlu 4 cells, its inhibitory potency was increased over that of wild-type (WT) protein, while the V826M mutation was less sensitive to the ligand than WT mGlu 4 , indicating that the molecule occupies the whole allosteric pocket ( Figure 1D ) and further supporting the binding mode proposed. Consistently, these mutations did not alter the potency of the mGlu 4 orthosteric agonist L-AP4 ( Figure S1 ).
The inclusion of an azobenzene group within the chemical structure of a drug confers potential photochromic activity to the molecule (Broichhagen et al., 2015) . Two common properties of reported azobenzene ligands impose limitations for biological applications. First, the light source used to induce the trans to cis isomerization is usually in the UV-violet range, which is arguably not optimal for in vivo applications because of reduced tissue penetration and potential cell damage. The second limitation derives from the thermal stability of cis-azobenzene in the dark, which may require a second wavelength illumination to return to the trans isomer for efficient switching. In the present work, we could circumvent these possible drawbacks since OptoGluNAM4.1 isomerizes with blue light and shows a quick back isomerization when dark conditions are recovered (Figure 2A) . OptoGluNAM4.1 exhibits a wide visible absorption band, and light sources from 420 nm to 460 nm were found to produce efficient trans to cis photoisomerization (Figures 2B (B) Dose-response curves of the orthosteric agonist L-AP4 or the allosteric agonist VU015041 in the presence of different doses of OptoGluNAM4.1 in wild-type, a mutated mGlu 4 receptor (which is insensitive to glutamate), and an ECD-truncated mGlu 4 receptor. (C) Localization of the OptoGluNAM4.1 binding site within a model of the transmembrane domain proposed by a protein docking study. Two amino acid positions (L756S and V826M) topologically delimit the allosteric binding pocket. (D) Dose-response curves for wild-type and mutated receptors after stimulation with the agonist both in the presence and in the absence of OptoGluNAM4.1. Each data point corresponds to the mean ± SEM of at least three experiments performed. and S2A). This change was reversed by applying red light (630 nm) or by spontaneous thermal relaxation when the blue illumination was discontinued. Absorption was maintained in several light-switching cycles ( Figure S2A ). Interestingly, cis to trans relaxation in the dark was very fast ( Figures 2C and S2A) , and it should enable the photocontrol of mGlu 4 activity with a single illumination wavelength (Chi et al., 2006) .
Single-cell calcium imaging experiments demonstrated the ability of OptoGluNAM4.1 to optically control mGlu 4 . Indeed, the application of OptoGluNAM4.1 in the dark impeded the activation of the receptor by L-AP4, and 430 nm illumination restored L-AP4 induced intracellular calcium responses (Figures 2D and S2B and Movie S2). The OptoGluNAM4.1 activity was only abolished upon illumination conditions, and it was rapidly reestablished in the dark as expected from its fast relaxation dynamics. The quantification of the single-cell experiments showed significant differences between illuminated and dark situations (Figure 2E) , whereas no light effect was found for the antagonism of L-AP4-induced-activity by LY341495, a general non-photoswitchable orthosteric antagonist of mGlu receptors ( Figure 2F ).
The OptoGluNAM4.1 molecule contains a 2-chloroethyl substituent at nitrogen, similar to that present in drugs such as chlorambucil or bendamustine, which belong to the nitrogen mustard family of anticancer agents. It is well known that the mechanism of action of these molecules involves an electrophilic alkylation and cross-linking of DNA (Gandhi, 2002) , where the N-2-chloroethyl substituent plays an essential role, generating a highly reactive aziridinium electrophile that reacts with nucleophiles present in the biomolecules after binding. This chemical reactivity has also been employed in the development of GPCR covalent ligands (Weichert and Gmeiner, 2015) . We hypothesized that a similar mechanism could take place in our case and could explain some of the pharmacological effects observed with OptoGluNAM4.1. A light-dependent NAM effect was maintained in mGlu 4 -expressing cells even after extensive washout of the allosteric ligand ( Figure S2B ). This could indicate conjugation of the compound to the protein receptor, compatible with the precedents of the reactivity of 2-chloroethyl anilines after binding to DNA or proteins. To better study this phenomenon, single-cell experiments were conducted in which a meticulous washing protocol was applied ( Figures 2G and  S2C) . Again, we observed that the antagonistic effect persisted and that this could be switched off after illumination and restored in the dark, indicating photoreversible receptor activation after removal of the ligand in solution. These results were in contrast with those obtained with the closely related compound 2 (Figures 2G and S2C ) containing a hydroxyl group instead of the chlorine atom at the nitrogen substituent ( Figure S2B ). Of note, compound 2 is unable to chemically react with the protein residues, but it conserves antagonist properties similar to OptoGluNAM4.1 albeit at higher concentration ( Figure S2B ).
We independently confirmed this permanent effect in inositol phosphate (IP) endpoint assays. When OptoGluNAM4.1 was incubated for 20 min and after a thorough washing protocol, the dose response of the mGlu 4 agonist L-AP4 corroborated a remaining NAM effect, evidenced by the inhibition of the constitutive activity ( Figure 2H ). This effect was decreased by the application of blue light, thus suggesting that the activity was due to the presence of covalently bound OptoGluNAM4.1 ( Figure 2I ). GPCR covalent allosteric ligands are scarce (Davie et al., 2014) in spite of their singular pharmacological profile.
We next implemented in vivo assays to determine OptoGluNAM4.1 activity in animal behavior. We first tested its mGlu 4 NAM activity in a mouse model of inflammatory chronic pain. One week after injection of complete Freund's adjuvant (CFA), an increase of mechanical hypersensitivity was observed for all animal groups, which was reduced by activation of spinal mGlu 4 receptors following intrathecal injection of the mGlu 4 orthosteric agonist LSP4-2022 (Vilar et al., 2013 ). OptoGluNAM4.1 was able to block the analgesic effect induced by LSP4-2022 (Figures 3A and S3) in line with its mGlu 4 antagonist activity, whereas OptoGluNAM4.1 alone did not have any measurable effect. At the concentrations used here, the LSP4-2022 inhibition of mechanical hypersensitivity is lost in mGlu 4 knockout animals (Vilar et al., 2013) , and therefore this compound is believed to selectively exert its effects through the mGlu 4 receptor. The reversal of LSP4-2022 physiological effects by OptoGluNAM4.1 suggests that its action is likely exerted through mGlu 4 , although a partial contribution of mGlu 7 antagonism cannot be ruled out ( Figure S1 ). Overall, these results confirmed that OptoGluNAM4.1 is active and suitable for in vivo experimentation in mice.
To test the light-dependent activity in vivo, we set up behavioral assays in transparent zebrafish larvae, which are amenable to illumination (Portugues et al., 2013) . In comparison with mammals, the mGlu family of receptors in zebrafish have similar expression patterns and high amino acid sequence similarity (Haug et al., 2013) . The activity of OptoGluNAM4.1 in water was evaluated by monitoring zebrafish locomotion. In the dark, OptoGluNAM4.1 treatment increased the free-swimming distance over untreated control animals ( Figure 3B ). We next compared its effects with those exerted by Alloswitch-1, an azobenzene selective NAM of mGlu 5 (Pittolo et al., 2014) . In the absence of illumination, Alloswitch-1 was found to exert an inhibitory action on the fish locomotion ( Figure S3 and Movie S5) over that of untreated controls. The opposite effects found for OptoGluNAM4.1 and Alloswitch-1 on animal behavior ( Figures 3B and S3 ) are consistent with the opposite synaptic roles of these receptors. Indeed, the activation of mGlu 4 (and also mGlu 7 ) is known to inhibit synaptic glutamate release, whereas mGlu 5 has a positive modulatory effect on neuronal activity (Nicoletti et al., 2011) . We next tested the effect of cis-trans isomerization by illumination of the zebrafish larvae. In vivo optical control of OptoGluNAM4.1 and Alloswitch-1 on zebrafish demonstrated reversibility (Figures 3C, S3C , and S3E and Movies S3, S4, and S5). The increase in the free-swimming distance observed in animals treated with OptoGluNAM4.1 over the untreated control group was reduced to similar levels upon illumination of the larvae with blue light. On the contrary, the reduced free-swimming distance elicited in vivo by Alloswitch-1 was not only reversed by 380 nm illumination but increased over untreated controls, in agreement with the activity rebounding previously reported in a heterologous cellular system expressing mGlu5 (Pittolo et al., 2014) . It is worth noting the biological activity of these photoswitchable NAM compounds and the light-dependent effects induced in cells and living animals, thus highlighting the usefulness of photopharmacology in the discovery of new pharmacological paradigms.
SIGNIFICANCE
OptoGluNAM4.1 is the first mGlu 4 NAM compound with in vivo activity described to date. It can be useful as a tool to investigate the effects of mGlu 4 receptor (and eventually mGlu 7 ) both in cells and in living animals, and amenable to dissect the physiological roles of this receptor in the nervous system. Moreover, the OptoGluNAM4.1 advantageous photoswitch properties with blue-light isomerization and fast relaxation in the dark facilitate the safe and efficient control of receptor activity with a single illumination wavelength. OptoGluNAM4.1 permanent activity in endogenous mGlu 4 after washing out further increases the versatility of the photoswitchable ligand, expanding the molecular tool set in photopharmacology.
EXPERIMENTAL PROCEDURES

Synthesis of Molecules
A description of the synthesis of compounds OptoGluNAM4.1 (1) and compound 2 is given in the Supplemental Information.
In Vitro mGlu Receptor Functional Assay HEK293 cells were cultured and transfected by electroporation for expression of all rat mGlu receptors. We estimated IP accumulation using the IP-One HTRF kit (Cisbio Bioassays) both in dark and violet light illumination (LED plate; FCTecnics) as previously reported (Pittolo et al., 2014) . All points were realized in triplicate and read with a RUBYstar HTRF HTS microplate reader (BMG Labtech). Dose-response curves were fitted using Prism software (GraphPad). See Supplemental Experimental Procedures for detailed procedures.
Molecular Modeling
Following the protocol described previously (Rovira et al., 2015) , a model of mGlu4 was generated with Modeller 9.12 using the crystal structure of mGlu5. OptoGluNAM4.1 was introduced by docking using AutoDock Vina. Discovery studio visualizer (Accelrys Software) and Jalview 2.8 were used for protein structure and sequence analysis, respectively. See Supplemental Experimental Procedures for detailed procedures.
Photophysical Characterization
Absorption spectra were recorded on a Varian Cary 300 UV-visible spectrophotometer (Agilent Technologies) using a quartz cuvette. Photoisomerization was accomplished by irradiation with a 430 nm LED array (FCTecnics) or 630 nm LED (Photo Activation Universal Light, Geniul). Transient absorption measurements were registered in a nanosecond laser flash-photolysis system (LKII, Applied Photophysics) equipped with an Nd:YAG laser (Brilliant, Quantel) and a photomultiplier tube (Hamamatsu). See Supplemental Experimental Procedures for detailed procedures.
Single-Cell Calcium Imaging and Photostimulation HEK tsA201 cells were cultured, transfected, and seeded as previously reported (Pittolo et al., 2014) . Fura-2 AM was loaded into the cells, excited with a Polychrome V light source (Till Photonics), and the resulting images acquired with an inverted digital microscope (iMic, Till Photonics). The fluorescence ratio was calculated by the software (LA Arivis Browser 1.6, Arivis). Variations in intracellular calcium were evaluated with IgorPro 6.0.5 (WaveMetrics). Dose-response curves were fitted with Prism (GraphPad). Videos were edited from raw images using Fiji (ImageJ). See Supplemental Experimental Procedures for detailed procedures.
Mechanical Allodynia in a Mouse Pain Model Animals were treated in accordance with the European Community Council Directive 86/609. Experimental protocols were approved by the local authorities (regional animal welfare committee (CEEA-LR) with the guidelines of the French Agriculture and Forestry Ministry (C34-172-13). All efforts were made to minimize animal suffering and number.
A Von Frey assay on 8-to 10-week-old C57BL/6 mice was used to evaluate the effect of mGlu4 compounds. We chose a chronic inflammatory pain model induced by unilateral intraplantar injection of CFA (Mycobacterium tuberculosis; Sigma). Compounds were intrathecally administered. Data were analyzed with Prism software (GraphPad). See Supplemental Experimental Procedures for detailed procedures.
Zebrafish
Zebrafish experiments were conducted in accordance with the European Communities council directive 2010/63. WT Tupfel long-fin specimens were used for these experiments. Monitoring of animal locomotion was made with the Zebrabox using the optogenetic module (Viewpoint Life Sciences). One larvae per well was placed in a 96-well plate (BD Falcon) with E3 medium. Data were analyzed with Prism software (GraphPad 
